USSTOCK.TODAY
Regular Market
Log in Sign up

Johnson & Johnson records $25.4 billion in Q3 revenue driven by Tremfya demand

Pharmaceutical Technology ·

  1. 1J&J revenue for the quarter reached $25.4 billion, exceeding the analyst consensus estimate of $25.28 billion.
  2. 2Tremfya revenue surged 68.3% to reach $2.4 billion.
  3. 3Johnson & Johnson raised its 2026 guidance.

So what's the key point?

Johnson & Johnson earned more money than experts expected due to strong drug sales. As the company's performance improved, it also raised its targets through 2026.

Source Pharmaceutical Technology · View original ↗

Related 3-line summaries

S&P 500 earnings growth continues as AI investment drives surge in corporate profits International Business Times · 1h agoBlackRock CEO Larry Fink Warns of Recession if Data Center Construction Halts The Wall Street Journal +3 · 1h agoDow Jones falls amid bank earnings and semiconductor weakness Schaeffer's Research · 1h ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news